FDA approves drug for women at cancer riskBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7168.1274a (Published 07 November 1998) Cite this as: BMJ 1998;317:1274
- Richard Woodman
The US Food and Drug Administration has approved tamoxifen for reducing the incidence of breast cancer in high risk women–a decision condemned as hasty by European specialists, who fear that many women will derive no benefit and will be at increased risk of endometrial cancer.
The landmark approval was based on results from the large North American breast …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial